feb 12, 2019: 1 p.m. - 2 p.m.
Shubert Complex - 6th floor
New national security regulations under the Foreign Investment Risk Review Modernization Act (FIRRMA) are changing the landscape for cross-border investments in biotechnology. In November 2018, new rules for a %u201Cpilot program%u201D apply to foreign investors into U.S. companies who now need to file with the Committee on Foreign Investment in the United States (CFIUS) to approve covered transactions before entering licensing deals or other equity investments. This session will update market participants on the evolving national security review process and its impact on the biotechnology industry, as well as consider how additional rules may impact future business development and investment opportunities.
Moderator: Lisa Schaefer, Director, Tax & Financial Services Policy, Biotechnology Innovation Organization (BIO)